These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 4461795)

  • 1. Problems of interpretation in the chemical pathology of schizophrenia.
    Pope A
    J Psychiatr Res; 1974; 11():265-72. PubMed ID: 4461795
    [No Abstract]   [Full Text] [Related]  

  • 2. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation.
    Jarskog LF; Selinger ES; Lieberman JA; Gilmore JH
    Am J Psychiatry; 2004 Jan; 161(1):109-15. PubMed ID: 14702258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CHOLINESTERASE ACTIVITY OF THE CEREBRAL CORTEX IN MAN].
    ZACCHEO D; VIALE G
    Ann Histochim; 1963; 8():259-61. PubMed ID: 14169852
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex.
    Gabriel SM; Davidson M; Haroutunian V; Powchik P; Bierer LM; Purohit DP; Perl DP; Davis KL
    Biol Psychiatry; 1996 Jan; 39(2):82-91. PubMed ID: 8717605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia.
    Cecil KM; Lenkinski RE; Gur RE; Gur RC
    Neuropsychopharmacology; 1999 Feb; 20(2):131-40. PubMed ID: 9885793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced GABA uptake sites in the temporal lobe in schizophrenia.
    Simpson MD; Slater P; Deakin JF; Royston MC; Skan WJ
    Neurosci Lett; 1989 Dec; 107(1-3):211-5. PubMed ID: 2616032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia.
    Simpson MD; Slater P; Deakin JF
    Biol Psychiatry; 1998 Sep; 44(6):423-7. PubMed ID: 9777172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia.
    Deakin JF; Slater P; Simpson MD; Gilchrist AC; Skan WJ; Royston MC; Reynolds GP; Cross AJ
    J Neurochem; 1989 Jun; 52(6):1781-6. PubMed ID: 2566649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic disconnection between the mediodorsal nucleus of the thalamus and cortical Brodmann's areas of the left hemisphere in schizophrenia.
    Mitelman SA; Byne W; Kemether EM; Hazlett EA; Buchsbaum MS
    Am J Psychiatry; 2005 Sep; 162(9):1733-5. PubMed ID: 16135634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NOS1AP protein levels are altered in BA46 and cerebellum of patients with schizophrenia.
    Hadzimichalis NM; Previtera ML; Moreau MP; Li B; Lee GH; Dulencin AM; Matteson PG; Buyske S; Millonig JH; Brzustowicz LM; Firestein BL
    Schizophr Res; 2010 Dec; 124(1-3):248-50. PubMed ID: 20605702
    [No Abstract]   [Full Text] [Related]  

  • 11. N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study.
    Nudmamud S; Reynolds LM; Reynolds GP
    Biol Psychiatry; 2003 Jun; 53(12):1138-41. PubMed ID: 12814865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased manganese-superoxide dismutase activity in postmortem brain from neuroleptic-treated psychotic patients.
    Loven DP; James JF; Biggs L; Little KY
    Biol Psychiatry; 1996 Aug; 40(3):230-2. PubMed ID: 8830959
    [No Abstract]   [Full Text] [Related]  

  • 13. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
    Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
    J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography.
    Wolkin A; Jaeger J; Brodie JD; Wolf AP; Fowler J; Rotrosen J; Gomez-Mont F; Cancro R
    Am J Psychiatry; 1985 May; 142(5):564-71. PubMed ID: 3872603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Oct-6, a POU III domain transcription factor, in schizophrenia.
    Ilia M; Beasley C; Meijer D; Kerwin R; Cotter D; Everall I; Price J
    Am J Psychiatry; 2002 Jul; 159(7):1174-82. PubMed ID: 12091196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzodiazepine receptor distribution and diazepam binding in schizophrenia: an exploratory study.
    Schröder J; Bubeck B; Demisch S; Sauer H
    Psychiatry Res; 1997 Feb; 68(2-3):125-31. PubMed ID: 9104759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomere quantification in frontal and temporal brain tissue of patients with schizophrenia.
    van Mierlo HC; Wichers CGK; He Y; Sneeboer MAM; Radstake TRDJ; Kahn RS; Broen JCA; de Witte LD
    J Psychiatr Res; 2017 Dec; 95():231-234. PubMed ID: 28910708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis.
    Brugger S; Davis JM; Leucht S; Stone JM
    Biol Psychiatry; 2011 Mar; 69(5):495-503. PubMed ID: 21145039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect.
    Heimberg C; Komoroski RA; Lawson WB; Cardwell D; Karson CN
    Psychiatry Res; 1998 Aug; 83(2):105-15. PubMed ID: 9818736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intralaminar distribution of neurotransmitter-related enzymes in cerebral cortex of Alzheimer's disease.
    Sorbi S; Piacentini S; Amaducci L
    Gerontology; 1987; 33(3-4):197-202. PubMed ID: 3653702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.